H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $100 from $90 and keeps a Buy rating on the shares. The firm cites the positive top-line results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Bridgebio Pharma (BBIO) Q4 Earnings Cheat Sheet
- BridgeBio price target raised to $100 from $94 at Bernstein
- Tyra Biosciences price target raised to $53 from $37 at Wedbush
- BridgeBio price target raised to $83 from $81 at Oppenheimer
- BridgeBio (BBIO): Buy Rating Supported by Strong Phase 3 Infigratinib Data in Achondroplasia and Growing Commercial Momentum